Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology, and Peptidase Inhibition and Analysis.
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma
Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Genetic factors influencing the risk of multiple myeloma bone disease
Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients
<scp>TRIM</scp>13 (<scp>RFP</scp>2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of <scp>NF K</scp>appa <scp>B</scp> pathway and proteasome activity
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy